Amneal Pharmaceuticals, Inc. AMRX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s accounts receivable?
- Amneal Pharmaceuticals, Inc. (AMRX) reported accounts receivable of -$44.01M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s accounts receivable changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s accounts receivable decreased by 108.1% year-over-year, from -$21.15M to -$44.01M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s accounts receivable?
- Over 5 years (2020 to 2025), Amneal Pharmaceuticals, Inc.'s accounts receivable has grown at a -56.2% compound annual growth rate (CAGR), from $638.9M to $10.34M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.